Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A live Pharma & Life Sciences Pharmacovigilance file in a biologics company planning a biosimilar pathway now turns on inspection-readiness findings at a CMO after a site-change that invalidates stability claims. Pediatric-plan strategist should state what that extract proves for whether to drop a secondary endpoint that will dominate the AdCom.

DECISION Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Inspection-readiness findings at a CMO reads as Proceed under protocol once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population. 2. Inspection-readiness findings at a CMO is closer to Pause the pathway after a site-change that invalidates stability claims; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in inspection-readiness findings at a CMO for pediatric-plan strategist in a biologics company planning a biosimilar pathway. 4. Inspection-readiness findings at a CMO is missing the fact pediatric-plan strategist needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 4. For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for pediatric-plan strategist in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for pediatric-plan strategist - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for pediatric-plan strategist in a biologics company planning a biosimilar pathway